ADARx Pharmaceuticals, Inc.
San Diego, California, United States · Biotechnology, Healthcare, Health Care
ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ADRX)
- Website
- www.adarx
- Company page
Recent activity at ADARx Pharmaceuticals, Inc.
- : SEC 8-K (8.01): On September 13, 2026, ADARx Pharmaceuticals, Inc. entered into a Common Stock Purchase Agreement with AbbVie Inc. The agreement involved a private placement of common stock that allows AbbVie to purchase up to $100 million worth of shares, equating to approximately 5,255,542 shares based on the public offering price of $17.00 per share. The closing of this transaction occurred concurrently with the IPO on September 28, 2026. This strategic agreement indicates a significant investment by AbbVie, expected to enhance ADARx's capital position and potentially broaden its strategic collaborations in the biotechnology sector.
- : ADARx Pharmaceuticals
- : Adarx Pharmaceuticals, A Leader In Next Generation Rna Therapeutics, Announces Oversubscribed $200 Million Series C Financing
- : ADARx Pharmaceuticals
- : Adarx Pharmaceuticals Raises $46 Million As Lead Product Enters The Clinic
- : ADARx Pharmaceuticals, Inc.
- : ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2023 | Venture | $200.0M |
| Aug 2023 | Series C | $200.0M |
| Jan 2023 | Venture | $46.0M |
| Jan 2023 | Funding Round | $46.0M |
| Aug 2021 | Venture | $75.0M |
Leadership
- Zhen Li, PRESIDENT & CEO
- Christopher Claeboe, Director
- Zhen Li, Director
- Zhen Li, Executive Officer, Director
- Carl Gordon, Director
- Hongbo Lu, Director
- Erez Chimovits, Director
- Christopher Claeboe, VICE PRESIDENT, CMC AND MANUFACTURING
- Rui Zhu, Executive Officer
Verified email and direct lines for ADARx Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
ADARx Pharmaceuticals, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
ADARx Pharmaceuticals, Inc. in the news
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - Yahoo Finance (Sep 24, 2026)
- ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO - Reuters (Sep 25, 2026)
- ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public - BioSpace (Sep 25, 2026)
- ADARx scores upsized $446M IPO, while City maps out Nasdaq plans - Fierce Biotech (Sep 25, 2026)
- ADARx Pharmaceuticals raised $446 million in a biotech IPO backed by AbbVie - Quartz (Sep 25, 2026)
- Adarx Pharmaceuticals Files For US IPO to Fund RNA Treatment - Bloomberg.com (Sep 04, 2026)
- ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering - The Manila Times (Oct 01, 2026)
- ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention? - Yahoo Finance (Sep 27, 2026)
Companies similar to ADARx Pharmaceuticals, Inc.
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care, Therapeutics
- Beam Therapeutics Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Enliven Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About ADARx Pharmaceuticals, Inc.: questions and answers
What does ADARx Pharmaceuticals, Inc. do?
ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by
Where is ADARx Pharmaceuticals, Inc. headquartered?
ADARx Pharmaceuticals, Inc. is headquartered in San Diego, California, United States.
Has ADARx Pharmaceuticals, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for ADARx Pharmaceuticals, Inc.. The most recent, $200.0M, was in Aug 2023.
Who leads ADARx Pharmaceuticals, Inc.?
Zhen Li is a PRESIDENT & CEO at ADARx Pharmaceuticals, Inc..
What is the latest news on ADARx Pharmaceuticals, Inc.?
On Sep 28, 2026, SEC 8-K (8.01): On September 13, 2026, ADARx Pharmaceuticals, Inc. entered into a Common Stock Purchase Agreement with AbbVie Inc. The agreement involved a private placement of common stock that allows AbbVie to purchase up to $100 million worth of shares, equating to approximately 5,255,542 shares
Is ADARx Pharmaceuticals, Inc. a public company?
Yes. ADARx Pharmaceuticals, Inc. is publicly traded under the ticker ADRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy